SARS-CoV-2 Vaccine

About Auro Vaccines

Auro Vaccines, a wholly-owned subsidiary of Aurobindo Pharma USA, is a clinical-stage biotech focused on a fundamental new approach to vaccine design. Its proprietary PBS Vax™ platform allows precise 'tuning' of immune responses to overcome the shortcomings of current DNA and classic prophylactic vaccines. The company has established a pipeline targeting high-unmet-need areas like HPV-associated cervical dysplasia, SARS-CoV-2, Chikungunya, and RSV, and maintains significant partnerships with entities like Emergent BioSolutions and CEPI for filovirus and other outbreak pathogen vaccines.

About Phylex BioSciences

Phylex BioSciences is a private, pre-clinical stage biotech leveraging advanced AI and deep learning to design next-generation mRNA nanoparticle vaccines. Its core technology platform aims to overcome limitations of current vaccines, such as immune imprinting and short-lived immunity, by encoding for highly immunogenic nanoparticles. The company's pipeline targets high-fatality and emerging viruses like Nipah, SARS-CoV-2, Chikungunya, West Nile, and human metapneumovirus, positioning it in the growing field of proactive pandemic preparedness.

About Epygen Biotech

Epygen Biotech is a private, US-based biopharmaceutical company founded in 2019, specializing in the development and manufacturing of biosimilar and novel therapeutic proteins. Its pipeline includes programs in oncology (Pegfilgrastim, Bevacizumab), cardiovascular (Recombinant Streptokinase), hormones (Teriparatide), and vaccines (SARS-CoV-2), supported by in-house CDMO capabilities. The company's strategy centers on leveraging its recombinant protein technology platform to produce high-quality, affordable biologics for global markets, though it appears to be in a pre-revenue or early development stage.

Therapeutic Areas

Other Prevention of COVID-19 Drugs